Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: Study protocol

There is no established standard chemotherapy for recurrent pediatric solid tumors such as neuroblastoma and sarcoma. Since some of these tumor cells show dysfunctions in homologous recombination repair, the goal is to conduct a phase I study of olaparib, a poly(ADP-ribose) polymerase inhibitor. | Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: Study protocol

Bấm vào đây để xem trước nội dung
TỪ KHÓA LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG